Regulatory filing citing Transplantation paper — Natera, 2022-11-08
NateraNateraNASDAQ NTRA
Filings SEC · Quote Yahoo cited a paper published in Transplantation in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way it wrote the paper and the actual scope of the paper in order. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by Natera on 2022-11-08 was 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Transplantation in the press release attached to it. Translating the sentence citing the paper verbatim from the original text, it reads as follows.
Transplantation . 2022;10.1097/TP.0000000000004324. doi:10.1097/TP.0000000000004324 Oncology commercial highlights 8 Not for reproduction or further distribution.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only part of it. To answer the latter question, one must read the full paper. This article, which only read the abstract, cannot provide an answer.
The scope of the paper mentioned in the abstract is up to this point.
The paper title is Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study and it was published in Transplantation on 2022-10-03. The authors' affiliations are University of Alberta · The Metabolomics Innovation Centre · Natera (United States) · Lambda Instruments (United States). The summary published at the beginning of the paper is called abstract. What this article read was only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and a verified reading.
This prospective study examined 280 biopsy samples from kidney transplant patients, comparing three factors: donor-derived DNA fragments in the blood, donor-specific antibodies, and molecular findings from the tissue. The key finding is that more than half of the cases diagnosed with antibody-mediated rejection did not detect antibodies. In these cases, blood DNA fragments were elevated, while in biopsies without rejection, there was no correlation between antibodies and DNA fragments. The scope of this paper is that combining these three tests can detect rejection even when antibodies are not detected.
The details not addressed in the abstract remain in the full text and appendices. This article leaves gaps as they are. Readers are expected to determine which sentence in the abstract corresponds to the cited excerpts from the company.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion attributable to market movement is called excess return. Dates are counted only on days when the stock market is open, referred to as trading days. In terms of a calendar, 20 trading days is approximately one month. The excess return on the day of the filing and for the following month are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | −9.2% | The extent of movement before the filing |
| On the filing day | −0.7% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | −25.1% | One week |
| Accumulated over +1 to +20 trading days | −12.1% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -12.1% in this case is within the bottom 41% of the 142 samples, placing it in the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −12.1% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case falls within or outside the range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past ten years. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
There are four additional cases where the same company cited papers in 8-K filings, which are included in the table below.
| Filing date | Journal of the cited paper | Excess return over one month |
|---|---|---|
| 2021-11-04 | Clinical Journal of the American Society of Nephrology | −13.1% |
| 2023-02-28 | Journal of Genetic Counseling | +18.2% |
| 2024-08-08 | Journal of Clinical Oncology | +3.9% |
| 2025-11-06 | New England Journal of Medicine | +18.7% |
Documents issued by the company after the filing
Only item numbers are listed for the three 8-K filings issued by the company after the filing date. In 8-K filings without titles, item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the item number. The specific event is described in the original text of each link.
- 2022-11-16 8-K Items 1.01,8.01,9.01 — Material contract execution · Other events · Financial statements · Attached documents
- 2023-02-23 8-K Item 5.02,9.01 — Officer·Director changes · Financial statements·Exhibit
- 2023-02-28 8-K Item 2.02, 9.01 — Earnings Announcement · Financial Statements · Attached Documents
What This Article Does Not Answer
This article, which reads only abstracts, cannot answer what the paper reviewed, how it was done, or what it showed. How many times the paper cited by the company was cited afterward can be rechecked via OpenAlexOpenAlex
Data source · Website citation counts. What will be seen next is whether the company's next 8-K again cites the same paper.
Glossary
- 8-K
- A voluntary report submitted to the U.S. Securities and Exchange Commission when a listed company has something to inform shareholders. Categories are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder obtained by subtracting the market's overall return from the stock's return. It is used to observe the company's unique movement after removing the portion attributable to the market's collective rise or fall.
- Trading day
- A date counting only the days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details or limitations of the method.